ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2128

Anti–MDA5 Antibody Positive Dermatomyositis Is Not Always Associated with Recalcitrant Lung Disease or Mortality

Dipekka Soni1, David Maniscalco 2, Srihari Veeraraghavan 3, Justin Cheeley 3 and Arezou Khosroshahi 1, 1Emory University, Atlanta, GA, 2Emory University, Altanta, 3Emory University, Atlanta

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Amyopathic dermatomyositis, ILD, pulmonary complications and Idiopathis Inflammatory Myopathies (IIM)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Session Title: Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Individuals with autoantibodies against melanoma differentiation-associated protein 5 (MDA-5) are reported to have a significant risk of developing rapidly progressive and fatal interstitial lung disease (ILD).  It is important that as new DM‐specific antibodies emerge, the associated phenotype be carefully defined as this can greatly impact the choice of treatment and prognostication of patients. The goal of this study is to describe the clinical and radiologic features of anti-MDA‐5 antibody-positive patients in a North American cohort, and in doing so, we contrast the existing literature by highlighting that ILD was less severe than previously reported and most patients had more favorable outcomes with treatment.

Methods: This retrospective study characterized the clinical characteristics, lung function, HRCT findings, treatment and outcomes of MDA5-positive patients seen at at Emory University and affiliated hospitals.  

Results: Fourteen MDA5-positive and two borderline-positive cases were identified between 2013 to 2019. Median disease duration is 18 months (range: 4-84). 15/16 (92%) had clinically amyopathic dermatomyositis, 7/16 (40%) had cutaneous ulcers and 14/16 (87%) had ILD.  6/16 subjects (37%) developed severe ILD of which 3 died from hypoxemic respiratory failure.  Of the three patients that died from hypoxemic respiratory failure, one had severe pneumomediastinum.

Conclusion: Our data supports that MDA5 Ab-associated ILD can be severe and/or progressive in a significant number of patients, however, it is can be treatable and stabilized in most cases.  Borderline positive anti-MDA5 patients manifest a phenotype consistent with strong positive MDA5 patients.  Finally, an association with spontaneous mediastinum may contribute to mortality rates in more severe cases.

Table 1: Clinical Characteristics

Table 2: Serological Profile, HRCT characteristics, PFTs

Table 3: Therapeutic regimen and Disease Course


Disclosure: D. Soni, None; D. Maniscalco, None; S. Veeraraghavan, None; J. Cheeley, None; A. Khosroshahi, Exagen, 2.

To cite this abstract in AMA style:

Soni D, Maniscalco D, Veeraraghavan S, Cheeley J, Khosroshahi A. Anti–MDA5 Antibody Positive Dermatomyositis Is Not Always Associated with Recalcitrant Lung Disease or Mortality [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/anti-mda5-antibody-positive-dermatomyositis-is-not-always-associated-with-recalcitrant-lung-disease-or-mortality/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-mda5-antibody-positive-dermatomyositis-is-not-always-associated-with-recalcitrant-lung-disease-or-mortality/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences